Suppr超能文献

丙酸氯倍他索与倍他米松-17,21-二丙酸酯在肾上腺抑制方面的比较。

Comparison of clobetasol propionate and betamethasone-17,21-dipropionate with reference to adrenal suppression.

作者信息

Eriksen K

出版信息

Acta Derm Venereol. 1979;59(4):372-4.

PMID:92159
Abstract

32 adult hospitalized patients with common skin disorders were controlled in a double-blind comparison study with clobetasol propionate (Dermovat) and betamethasone-17,21-dipropionate (Diproderm) with regard to adrenal suppression. The latter, when assessed by plasma cortisol, was significantly greater in the dermovat-treated groups after the 1st and 2nd week with daily treatment with both 25 g and 15 g ointment. Daily treatment of skin areas greater than 25% with 25 g Diproderm also showed clear adrenal suppression, whereas no such effect was obtained with daily treatment with 10 g Diproderm of skin areas greater than 15%. In all cases, plasma cortisol levels were normal 1--2 weeks after the end of topical treatment.

摘要

在一项双盲对照研究中,对32例患有常见皮肤病的成年住院患者使用丙酸氯倍他索(得肤宝)和倍他米松-17,21-二丙酸酯(适确得)进行肾上腺抑制方面的对照。在第1周和第2周每日分别使用25 g和15 g软膏进行治疗后,通过血浆皮质醇评估发现,得肤宝治疗组的肾上腺抑制作用明显更强。每日使用25 g适确得治疗大于25%的皮肤面积也显示出明显的肾上腺抑制,而每日使用10 g适确得治疗大于15%的皮肤面积则未出现这种效果。在所有情况下,局部治疗结束后1至2周血浆皮质醇水平恢复正常。

相似文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验